Penn Medicine Provider
Hematology
Elizabeth Hexner, MD
5.0
(276)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West

About me

  • Medical Director, Center for Cellular Immunotherapies
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Columbia University
  • Residency: NewYork-Presbyterian/Columbia University Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

276 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
you can easily tell she is an expert in her field.
June 2025
5.0
5.0
efficient visit and kind people.
June 2025
5.0
5.0
best hematologist ever
May 2025
5.0
5.0
always available and takes care of all concerns

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Hexner is a Penn Medicine physician.

Qualifications and experience

My research

Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM. Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial , Nat Med: 2025


Verschraegen CF, Hashibe M, Neill US, Pirl W, Hexner EO, O'Connell A; NASDC Consortium. NCI Awardee Skills Development Consortium (NASDC): a Successful Novel Educational Effort to Maintain Early Academic Competitiveness: PART 1-Overview of the NASDC Coordinating Center , J Cancer Educ: 2025


Myers RM, DiNofia AM, Li Y, Diorio C, Liu H, Wertheim G, Fraietta JA, Gonzalez V, Plesa G, Siegel DL, Iannone E, Shinehouse L, Brogdon JL, Taylor C, Jadlowsky JK, Hexner EO, Engels B, Baniewicz D, Callahan C, Ruella M, Aplenc R, Barz Leahy A, McClory SE, Rheingold SR, Wray L, June CH, Maude SL, Frey NV, Grupp SA. CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy , J Immunother Cancer, 13: 2025,e011549


Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv: 2025


Shannon R. McCurdy, Anthony D Sung, Rebecca T. Brown, Marni Kessler, Nelson J. Chao, Thuy T. Koll, Alfred Fisher, Ernaya Johnson, Meagan Lew, Lauren Bohannon, Sanghee Hong, Pashna Munshi, Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Daria Babushock, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, Vijaya Raj Bhatt, Phyllis Gimotty Machine Learning Models Demonstrate Gait Speed As the Best Predictor of Survival and Relapse-Free Survival in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation , Transplantation and Cellular Therapy: 2025


Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Mr. Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, Shannon R. McCurdy, David L Porter, Keith W. Pratz, Jacqueline Smith, Pashna Munshi Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation , Transplantation and Cellular Therapy: 2025


Ashley D. Hadjis, Honghong Sun, Yangzhu Du, Rebecca T. Brown, Pashna Munshi, Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, Shannon R. McCurdy Graft-Versus-Host Disease (GVHD) and Senescence-Associated Biomarkers Correlate with Frailty and Survival in Older Adults Undergoing Hematopoietic Cell Transplantation (HCT) , Transplantation and Cellular Therapy: 2025


Nasheed M. Hossain, Mr. Christopher J. Catania, Stefan K. Barta, Noelle V. Frey, Saar I. Gill, Elizabeth O Hexner, Mary Ellen Martin, Shannon R. McCurdy, Pashna Munshi, Jacqueline Smith, Vikram R Paralkar, Ellen Kim, Alain Rook, Alison W. Loren, David L Porter Leveraging Radiation and Graft Versus Lymphoma Effect for the Management of Relapsed/Refractory Cutaneous T-Cell Lymphoma , Transplantation and Cellular Therapy: 2025


Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nat Med: 2025


Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2025